Log in to search using one of your social media accounts:


MyoKardia ’s Phase II trial for oHCM drug meets endpoints

MyoKardia has reported positive top-line results from the first cohort of its Phase II PIONEER-HCM clinical trial of mavacamten in patients with symptomatic, obstructive hypertrophic cardiomyopathy (oHCM).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Speckle tracking imaging in hypertrophic cardiomyopathy : A powerful tool in search of an unfavorable substrate? Herz. 2017 Dec 12;: Authors: Rigopoulos AG, Ali M, Sakellaropoulos S, Matiakis M, Teren M, Pantazis A, Noutsias M PMID: 29234844 [PubMed - as supplied by publisher]
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
This study surveyed 90 adult probands and relatives with a personal or family history of cardiomyopathy from a single hospital-based cardiac genetic program to determine the psychosocial impact of genetic testing for cardiomyopathies. Standardized psychological instruments including an adapted Multidimensional Impact of Cancer Risk Assessment (aMICRA), Impact of Event Scale (IES), and Satisfaction with Decision (SWD) scales were utilized. Patients with positive genetic test results had higher scores for intrusive thoughts, avoidance, and distress when compared to those with negative genetic test results and were also more ...
Source: Journal of Genetic Counseling - Category: Genetics & Stem Cells Source Type: research
This article reviews both pharmacological and non-pharmacological interventions to improve outflow tract obstruction and symptoms, and provides an algorithm for addressing the symptomatic obstructive patient. Expert commentary: Current options for hypertrophic cardiomyopathy allow the majority of patients to live their lives with no more than NYHA Class 2 heart failure symptoms. Treatment algorithms can add in identification of patients who may benefit from advanced therapies, and should be instituted routinely to improve care for the majority of patients with symptomatic hypertrophic cardiomyopathy. PMID: 29231770 [Pu...
Source: Expert Review of Cardiovascular Therapy - Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research
Isoprenaline is predominantly beta stimulant, a synthetic sympathomimetic amine. Is the isopropyl derivative of norepinephrine. Main use in Cardiology is to enhance the heart rate. It is useful in severe bradycardia where its effect can be titrated by setting up an infusion. Sometimes it can produce hypotension due to systemic vasodilation. It has pulmonary vasodilatory effects as well. Isoprenaline infusion can be used in congenital and acquired complete heart blocks to increase the ventricular rate when pacing is not immediately feasible. Isoprenaline challenge has been used during hemodynamic studies in cathlab to induc...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Cardiology Source Type: blogs
Checkpoint inhibitors induce a plethora of immune-related adverse events (irAEs) including autoimmune colitis, hepatitis, endocrinopathies, and rarer side effects like neuritis. Here, a case of autoimmune cardiomyopathy (grade 3 CTCAE) and myocarditis under combination therapy with nivolumab plus ipilimumab in a 72-year-old melanoma patient is reported. Treatment induced a partial response for 14 months. However, after 10 infusions the patient developed dyspnea, edema of the legs, ascites and a weight gain of 10 kg because of a decompensated heart insufficiency with a reduced ejection fraction from formerly 48%&ndas...
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Brief Communication Source Type: research
Authors: Cao Y, Zhang PY Abstract Hypertrophic cardiomyopathy (HCM) is a complex but common monogenic cardiovascular disorder characterized by unexplained non dilated left ventricular (LV) thickening in the absence of another cardiac or systemic disease. The condition is associated with sudden and unexpected death in young individuals including trained athletes. HCM represents a genetic disorder caused by mutations in genes encoding sarcomeric proteins of the cardiac myocyte. This review article discusses the genetics behind HCM, its clinical presentation, and diagnosis and the present-day pharmacological managemen...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Michelle M. Monasky, Giuseppe Ciconte, Luigi Anastasia, Carlo Pappone
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Conclusion Oriental nomenclature is necessary not only for anatomist but also for electrocardiographers. Breadth of papillay muscle should be taken into morphometric account as for screening of hypertrophic cardiomyopathy. Proper anatomical knowledge is crucial for clinicians, surgeons and radiologists. Graphical abstract
Source: Indian Heart Journal - Category: Cardiology Source Type: research
Richard Payne, MDThe wisdom of humans tinkering with nature has been challenged throughout the ages based on a common storyline: humans unwisely tamper with nature with disastrous consequences for the creator when we cross a line previously reserved for the deity. Three decades ago, in the early days of gene engineering, scientists raised ethical and moral concerns about “playing God.” They weren’t opposed to interrupting the natural order to cross breed animals and plants or to cure or treat disease. Rather, they warned against exercising the power of science and technology without sufficient regard for ...
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: Health Care CRISPR-Cas9 Genomic Science germline gene editing syndicated Source Type: blogs
AbstractMyocardial perfusion-single-photon emission computed tomography (MP-SPECT) is used to evaluate microvascular dysfunction and coexisting coronary artery disease in patients with hypertrophic cardiomyopathy (HCM). Phase analysis in gated MP-SPECT can provide additional information on left ventricular (LV) dyssynchrony, while the extent of late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) imaging is an important prognostic factor in patients with HCM. We, therefore, sought to investigate the relationship of dyssynchrony by phase analysis on gated MP-SPECT and LGE on CMR imaging in 22 patients with ...
Source: Heart and Vessels - Category: Cardiology Source Type: research
More News: Cardiology | Cardiomyopathy | Clinical Trials | Heart | Hypertrophic Cardiomyopathy | Pharmaceuticals